Marquette General Cancer Center

 

Myelodysplasia

 

Study Name - ECOG E2905

 

Study Description - Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia

 

IRB Open Date - 04/13/2011

 

Consent

 

Data Privacy Statement for Research Studies

 

 

 

<< Back